Pembrolizumab trials for Pancreatic cancer

All Pembrolizumab trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Pancreatic cancer

• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
  NCT05365581 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 46 locations
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
  NCT06400472 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 158 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
  NCT07094113 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
  NCT07166601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
  NCT05462496 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
  NCT05132504 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
  NCT06384560 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
  NCT05093231 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
  NCT05732831 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
  NCT04429542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations

Common questions

How many trials study Pembrolizumab for Pancreatic cancer?

17 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.